Concurrent chemotherapy (5-fluorouracil and cisplatin) and radiation therapy followed by surgery for T4 squamous cell carcinoma of the esophagus
- 28 January 1999
- journal article
- clinical trial
- Published by Wiley in Journal of Surgical Oncology
- Vol. 70 (1) , 25-32
- https://doi.org/10.1002/(sici)1096-9098(199901)70:1<25::aid-jso5>3.0.co;2-m
Abstract
Background and Objectives Since the prognosis of patients with T4 squamous cell carcinoma (SCC) of the esophagus is extremely poor, an effective multimodal treatment needs to be established. Methods Forty‐five patients with SCC of the esophagus at the T4 classification of the disease but no hematogenous metastasis were treated with concurrent chemoradiation therapy followed by surgical resection. Twenty‐eight patients were treated with a regimen (protocol A) of 5‐fluorouracil 750 mg/m2 on days 1–5 and 22–26, and cisplatin 70 mg/m2 on days 1 and 22. The remaining 17 patients were treated with a modified regimen (protocol B) of 5‐fluorouracil 400 mg/m2 and cisplatin 10 mg/m2 on days 1–5, 8–12, 15–19, and 22–26. Radiation was delivered daily for 5 days/week for 4 weeks at the rate of 2 Gy/day to a total dose of 40 Gy in both protocols. Results A major clinical response was observed in 29 [3 complete response (CR) and 26 partial response (PR)] patients (64.4%). Twenty‐eight patients (62.2%) underwent esophagectomy with no postoperative death. The median survival time of the resected patients (959 days) was significantly longer than that of the non‐resected patients (178 days). Protocol B showed significantly higher pathologic effectiveness than protocol A. The pathologic CR rate for the main tumors was 1 (6.3%) of 16 patients for protocol A and 7 (58.3%) of 12 patients for protocol B. The pathologic CR rate for metastasized lymph nodes was 4/11 (36.4%) for protocol A and 5/5 (100%) for protocol B. Good histological response of the main tumors correlated well with long survival. The treatments were well tolerated except for one treatment‐related death. Conclusions Concurrent chemoradiation therapy followed by surgery is an effective and safe multimodal therapy for patients with primary inoperable T4 SCC of the esophagus. J. Surg. Oncol. 1999;70:25–32.Keywords
This publication has 19 references indexed in Scilit:
- Preoperative chemoradiation followed by transhiatal esophagectomy for carcinoma of the esophagus: final report.Journal of Clinical Oncology, 1993
- Randomized Trial of Preoperative Chemotherapy for Squamous Cell Cancer of the EsophagusArchives of Surgery, 1992
- Low dose preoperative radiotherapy for carcinoma of the oesophagus: results of a randomized clinical trialRadiotherapy and Oncology, 1992
- Randomized clinical trial on the combination of preoperative irradiation and surgery in the treatment of esophageal carcinoma: Report on 206 patientsInternational Journal of Radiation Oncology*Biology*Physics, 1989
- Preoperative radiation and chemotherapy for localized squamous cell carcinoma of the esophagus: a RTOG studyInternational Journal of Radiation Oncology*Biology*Physics, 1988
- The value of preoperative radiotherapy in esophageal cancer: Results of a study of the E.O.R.T.C.World Journal of Surgery, 1987
- Combined therapies for squamous-cell carcinoma of the esophagus, a Southwest Oncology Group Study (SWOG-8037).Journal of Clinical Oncology, 1987
- Preoperative chemotherapy and radiation therapy for patients with cancer of the esophagus: a potentially curative approach.Journal of Clinical Oncology, 1984
- Combined modality therapy for esophageal squamous cell carcinomaCancer, 1983
- SURGICAL TREATMENT OF ESOPHAGEAL CARCINOMA INFILTRATED TO THE ADJACENT ORGANSThe Japanese Journal of Gastroenterological Surgery, 1981